Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant neratinib and/or trastuzumab plus paclitaxel followed by doxorubicin/cyclophosphamide in HER2-positive locally advanced breast cancer
2013-004391-35Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Dec 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of neratinib, trastuzumab, paclitaxel, doxorubicin and cyclophosphamide in breast cancer (3 arms), sponsored by Puma Biotechnology, Inc. Primary endpoint: Pathologic complete response rate in breast and nodes. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-004391-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004391-35.